PAVmed Inc

PAVmed Inc(PAVM)资讯与事件

$4.920

-0.146 (-2.96%)收盘时

PAVM 资讯

PAVM 事件

8/5 09:00

Lucid Diagnostics' EsoGuard Test Recognized by Concert Coverage Policy

Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer. Concert establishes coverage policies that its client health plans can adopt. The policy cites sufficient evidence in published guidelines and peer-reviewed literature to definitively demonstrate improved health outcomes, and considers Lucid's EsoGuard Esophageal DNA Test medically necessary in patients who meet American College of Gastroenterology screening criteria.

7/16 10:00

PAVmed Trading Halted Due to Volatility

PAVmed trading halted, volatility trading pause

7/16 10:00

PAVmed Trading Resumes

PAVmed trading resumes

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始